|
MorphoSys AG: Premium Company ProfilePublished by: Datamonitor Published: Apr. 22, 2008 - 45 Pages Table of Contents
AbstractIntroductionMorphoSys is a biotechnology company focused on the research and development of antibody drugs. The company’s main technology platform includes HuCAL (Human Combinatorial Antibody Library), an innovative technology which allows rapid and automated production of high-affinity antibodies. Scope Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies Highlights The company currently has therapeutic and research alliances with the majority of the world’s largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestone payments as well as royalties on any end products. MorphoSys derives its entire revenues from technology access fees and fees derived from research and development agreements primarily with companies such as Bayer, DuPont Pharmaceuticals, ImmunoGen, Hoffman La Roche and GPC Biotech. Reasons to Purchase Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization . Please note: This is delivered as a Zip file. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||